UK markets close in 6 hours 56 minutes

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
97.000+1.100 (+1.15%)
At close: 04:08PM HKT
Full screen
Previous close95.900
Open97.600
Bid97.000 x 0
Ask97.050 x 0
Day's range96.600 - 99.500
52-week range77.250 - 148.000
Volume18,705,019
Avg. volume16,090,121
Market cap411.098B
Beta (5Y monthly)1.09
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date23 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est156.32
  • Business Wire

    Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

    Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics ("WuXi Bio") (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.

  • Business Wire

    Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, today announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio’s proprietary technology. This CD39 collaboration represents the fourth antibody development program on which the two companies have joined forces. Arcus was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for all further development and commercialization activities of such anti-CD39 antibodies.